Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine

British Journal of Clinical Pharmacology

Volumn 70, Issue 4, 2010, Pages 537-546

  Zamuner, Stefano ^a   Johnson, Brendan M ^b   Pagliarusco, Sabrina ^a   Fina, Paolo ^a   Peroni, Michela ^a   Fiore, Monica ^a   Adams, Laurel M ^b   Fernandes, Sofia A ^a  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United States)

Author keywords

casopitant; CYP450 3A4; midazolam; nifedipine; pharmacokinetics

Indexed keywords

CASOPITANT; CYTOCHROME P450 3A4; DEBRISOQUINE; MIDAZOLAM; NIFEDIPINE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CELLULITIS; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MIGRAINE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; PHARYNX DISEASE; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SOMNOLENCE; VOMITING;

ADULT; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDAZOLAM; MIDDLE AGED; NIFEDIPINE; PIPERAZINES; PIPERIDINES; RECEPTORS, NEUROKININ-1; YOUNG ADULT;

EID: 77956585060     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03729.x     Document Type: Article

References (20)

1. Hewitt NJ, LeCluyse EL, Ferguson SS. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations and in vitro-in vivo correlations. Xenobiotica 2007 37:1196 1224.
2. Zuber R, Anzenbacherova E, Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 2002 6:189 198.
3. Chu V, Einolf HJ, Evers R, Kumar G, Moore D, Ripp S, Silva J, Sinha V, Sinz M, Skerjanec A. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective. Drug Metab Dispos 2009 37:1339 1354.
4. Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Pharma Res 2001 18:1071 1080.
5. Gibbs MA, Hosea NA. Factors affecting the clinical development of cytochrome P450 3A substrates. Clin Pharmacokinet 2003 42:969 984.
6. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 1999 48:716 727.
7. Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 2002 30:1311 1319.
8. Pellegatti M, Bordini E, Fizzotti P, Roberts A, Johnson BM. Disposition and metabolism of radiolabelled casopitant in humans. Drug Metab Dispos 2009 37:1635 1645.
9. Lehmann JM, McKee DD, Watson M, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998 102:1016 1023.
10. Herrstedt J, Apornwirat W, Shaharyar A, Aziz Z, Roila F, Van Belle S, Russo MW, Levin J, Ranganathan S, Guckert M, Grunberg SM. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 2009 27:5363 5369.
11. Grunberg SM, Rolski J, Strausz J, Aziz Z, Lane S, Russo MW, Wissel P, Guckert M, Wright O, Herrstedt J. Efficacy and safety of casopitant mesylate, a neurokinin-1 (NK-1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009 10:549 558.
12. Streetman DS, Bertino JS Jr., Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000 10:187 216.
13. Ball SE, Scatina JA, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, Hall J. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4. Clin Pharmacol Ther 1999 66:288 294.
14. Inaba T, Otton SV, Kalow W. Debrisoquine hydroxylation capacity: problems of assessment in two populations. Clin Pharmacol Ther 1981 29:218 223.
15. Sternberg S. Memory-scanning: mental processes revealed by reaction time experiments. Am Sci 1969 57:421 457.
16. Sternberg S. High-speed scanning in human memory. Science 1966 153:652 654.
17. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003 31:815 832.
18. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006 316:336 348.
19. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interaction based on AUC increase by coadministration of standard drugs. Clin Pharmacokinet 2007 46:681 697.
20. Emend Capsules Package Insert. Whitehouse Station, NJ:Merck & Co., Inc., 2006.